MedTrace Logo

A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain

NCT01159119 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-01-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate two different treatments in subjects with chronic pancreatitis, exocrine pancreatic insufficiency and chronic abdominal pain.

Conditions

  • Chronic Pancreatitis

Interventions

DRUG

EUR-1066-A

Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.

DRUG

Zenpep

Capsules taken for daily for 28 days during treatment period 2

DRUG

EUR-1066-B

Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.

Sponsors & Collaborators

  • University of Florida

    collaborator OTHER

  • Forest Laboratories

    lead INDUSTRY

Principal Investigators

  • Phillip Toskes, MD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-02
Primary Completion
2011-07-01
Completion
2011-07-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01159119 on ClinicalTrials.gov